The Complement-based Drug Development Summit
November 14 - 16, 2017 - Boston UKHanson Wade
info@hansonwade.com
Phone:2125375898
The Complement-based Drug Development Summit is the first industry-dedicated meeting that focuses on the research and development of therapeutics to inhibit the complement pathway, providing safe and effective cures for a range of disease indications. Across 3 content-packed days, the field's thought leaders from Alexion, True North, GSK, Alnylam and many more will be sharing their insight and lessons learned, collectively enabling the community to: - Standardize Efficacy Assessment: Define the next steps toward achieving standardization of robust, functional assays in order to accurately determine treatment efficacy. - Optimize Clinical Trial Design: Analyze methods for improving clinical trial design with case studies in patient recruitment and stratification, targeting, dosing, endpoints and sample handling. - Manage Off-Target Effects: Enhance the management of off-target effects and approaches for minimizing infection risk. - Achieve Regulatory Approval: Learn how best to navigate the regulatory landscape, examining guidelines and expectations to ensure that drugs gain market approval smoothly. - Assess Inhibition Points: Analyze the most effective points of complement inhibition for the treatment of individual diseases and the selection of therapeutic approaches for inhibition.